CD274 and non-small cell lung carcinoma: Another RWD study observed an overall survival between 13.2 months (PD-L1 TPS < 1%) and 16.3 months (PD-L1 TPS 1–49%) in metastatic non-squamous NSCLC patients with an ECOG performance status from 0 to 1 who were treated with pembrolizumab plus pemetrexed–carboplatin [58].